• 免費註冊
  • 加入官方line@
  • 加入FB粉絲團

台股 » 個股 » 太景*-KY » 籌碼相關 » 券商分點績效 » 券商分點個股進出

太景*-KY

(4157)
可現股當沖
  • 股價
    10.80
  • 漲跌
    ▼0.05
  • 漲幅
    -0.46%
  • 成交量
    438張
  • 產業
    上櫃 生技醫療類股

  • 265人加入追蹤

    立即追蹤

  • 本地時間:13:30(已收盤)

     
太景*-KY (4157)籌碼相關－富邦-台中 券商分點個股進出
券商分點績效/獲利分析

透過統計各券商分點在長期買賣某個股的操作績效，來找出真正獲利的贏家所在券商分點，進而追蹤此贏家所操作的股票與軌跡。

股票投資新手教室：一秒知道是否上對大戶列車

富邦-台中 券商分點個股進出

富邦-台中 券商分點全部個股操作績效/獲利分析

日期買進張數買進均價賣出張數賣出均價收盤價買賣超60日均量成交佔比 大量交易提示
2025/01/1700.00410.7010.70-41,219-0.33%
2025/01/1500.001010.7510.70-101,213-0.82%
2025/01/141510.6900.0010.70151,2191.23%
2025/01/131310.902510.8810.70-121,215-0.99%
2025/01/1000.001711.3811.35-171,185-1.43%
2025/01/092811.1400.0011.25281,1562.42%
2025/01/031511.331511.4311.3001,1200.00%
2025/01/02111.3000.0011.3011,1110.09%
2024/12/3000.00911.6011.30-91,115-0.81%
2024/12/2715.111.681011.8511.505.11,1330.45%
2024/12/2620812.061012.0712.001981,15617.12% 大買/鉅額交易
2024/12/25410.9800.0011.0041,0960.36%
2024/12/2400.000.311.0010.95-0.31,103-0.03%
2024/12/190.411.0600.0010.900.41,1110.03%
2024/12/18211.2000.0011.2521,1070.18%
2024/12/160.111.3500.0011.200.11,1250.00%
2024/12/13511.4400.0011.4551,1240.44%
2024/12/12111.902211.9311.80-211,108-1.89%
2024/12/112411.8500.0011.85241,1062.17%
2024/12/094.211.9000.0011.854.21,1290.37%
2024/12/067.112.0000.0012.007.11,1220.63%
2024/12/05212.0800.0012.0521,1170.18%
2024/12/030.212.2500.0012.150.21,1320.02%
2024/11/261512.251012.3012.3051,1330.44%
2024/11/2500.001012.7812.25-101,121-0.89%
2024/11/2000.00112.4012.45-1928-0.11%
2024/11/154.112.1000.0012.004.19740.42%
2024/11/141.512.6000.0012.201.59320.16%
2024/11/1300.00413.1513.10-4879-0.45%
2024/11/120.113.4500.0013.250.18820.01%
2024/11/11113.5000.0013.5018650.12%
2024/11/07013.9000.0013.8508670.00%
2024/10/1600.00114.2514.25-11,107-0.09%
2024/10/111014.3000.0014.30101,1590.86%
2024/10/07114.9500.0014.8511,2640.08%
2024/10/0100.00415.1015.10-41,323-0.30%
2024/09/2700.00214.6014.55-21,270-0.16%
2024/09/23014.6500.0014.4001,3420.00%
2024/09/1800.00114.5014.55-11,398-0.07%
2024/09/0600.00113.9013.90-11,502-0.07%
2024/09/05014.1000.0013.9001,5380.00%
2024/09/040.214.0500.0013.950.21,6290.01%
2024/08/2700.00314.3014.35-31,770-0.17%
2024/08/26114.25114.3014.3001,8010.00%
2024/08/20014.7500.0014.8001,8410.00%
2024/08/1600.001014.6014.55-101,812-0.55%
2024/08/131014.201014.2514.2501,8990.00%
2024/08/091.214.3100.0014.301.21,9140.06%
2024/08/0600.00213.3013.35-21,887-0.11%
2024/08/050.513.65213.6013.45-1.51,901-0.08%
2024/08/0200.000.814.1014.00-0.81,840-0.04%
2024/07/262.114.101214.1014.10-9.91,918-0.52%
2024/07/2300.00214.2514.20-21,956-0.10%
2024/07/221114.1500.0014.15111,9760.56%
2024/07/19114.3500.0014.3011,9790.05%
2024/07/17014.85214.6514.75-22,056-0.10%
2024/07/160.214.55114.5014.50-0.92,249-0.04%
2024/07/120.614.7200.0014.650.62,8230.02%
2024/07/11414.50414.5014.5002,7980.00%
2024/07/1000.00514.5014.45-52,829-0.18%
2024/07/090.114.6000.0014.600.12,8240.00%
2024/07/0800.00314.9314.90-32,748-0.11%
2024/07/0500.001115.0615.10-112,713-0.41%
2024/07/0400.00315.1015.05-32,703-0.11%
2024/07/0300.009815.0715.05-982,701-3.63%
2024/07/0100.002515.2515.10-252,712-0.92%
2024/06/2800.002515.2515.15-252,704-0.92%
2024/06/2600.002015.3015.25-202,722-0.73%
2024/06/2500.006015.0815.05-602,714-2.21%
2024/06/2000.001415.0515.10-142,825-0.50%
2024/06/1900.001.115.2015.05-1.12,823-0.04%
2024/06/181415.3000.0015.10142,8200.50%
2024/06/13215.15215.1015.0002,7730.00%
2024/06/11115.454015.7815.55-392,706-1.44%
2024/06/071515.6400.0015.40152,6490.57%
2024/06/0510.115.35115.4015.409.12,5760.35%
2024/06/04115.2000.0015.2512,5830.04%
2024/06/030.115.2500.0015.200.12,6200.00%
2024/05/310.115.3000.0015.200.12,6160.00%
2024/05/291015.051115.1015.10-12,617-0.04%
2024/05/2800.00115.0515.05-12,616-0.04%
2024/05/2700.001015.0515.00-102,612-0.38%
2024/05/241515.0500.0015.05152,6170.57%
2024/05/2300.00315.2015.20-32,616-0.11%
2024/05/21515.60715.6015.60-22,619-0.08%
2024/05/20515.60315.6015.6522,6060.08%
2024/05/1700.001015.7515.55-102,580-0.39%
2024/05/1600.0010015.0515.10-1002,557-3.91%
2024/05/140.115.0500.0015.000.12,5750.00%
2024/05/104515.2700.0015.30452,5511.76%
2024/05/09415.3600.0015.3542,5400.16%
2024/05/0800.001514.9914.95-152,495-0.60%
2024/05/0700.004014.8514.85-402,493-1.60%
2024/05/0600.00815.0514.95-82,476-0.32%
2024/05/035715.14215.1015.00552,4782.22%
2024/05/027115.2800.0015.15712,4472.90%
2024/04/3000.003615.3515.35-362,429-1.48%
2024/04/292115.35115.4015.65202,4070.83%
2024/04/254015.4300.0015.50402,3451.71%
2024/04/2300.00115.7015.50-12,295-0.04%
2024/04/22215.80116.7515.6012,2470.04%
2024/04/1912016.93516.6516.451152,0415.63% 大買/鉅額交易
2024/04/18415.6817215.7315.75-1681,621-10.36% 大賣/鉅額交易
2024/04/17114.4500.0014.3511,4510.07%
2024/04/1630.114.3500.0014.2530.11,4492.08%
2024/04/153114.7800.0014.65311,4182.18%
2024/04/112015.0000.0014.90201,4381.39%
2024/04/101015.286615.2815.10-561,428-3.92%
2024/04/092015.1500.0015.20201,4331.40%
2024/04/023015.60415.7515.65261,4151.84%
2024/04/0100.006415.7115.70-641,403-4.56%
2024/03/2900.00215.4515.45-21,365-0.15%
2024/03/2800.001015.6015.45-101,349-0.74%
2024/03/271215.70315.6815.4591,3240.68%
2024/03/2620015.4300.0015.352001,29815.40% 大買/鉅額交易
2024/03/2500.00115.2515.40-11,273-0.08%
2024/03/214214.59814.5914.70341,2442.73%
2024/03/20214.387014.4014.35-681,238-5.49%
2024/03/19114.653014.6314.50-291,234-2.35%
2024/03/14114.6500.0014.6011,2530.08%
2024/03/130.114.60314.5014.50-2.91,259-0.23%
2024/03/1100.00214.5514.55-21,246-0.16%
2024/03/080.114.7500.0014.550.11,3350.00%
2024/03/071014.45114.7514.7591,4920.60%
2024/03/041114.87115.0514.85101,6300.61%
2024/02/2900.00415.0515.10-41,896-0.21%
2024/02/23115.301515.3215.10-141,879-0.74%
2024/02/22115.60115.5515.2501,8640.00%
2024/02/21115.7000.0015.6511,8490.05%
2024/02/19415.65115.7015.5031,8350.16%
2024/02/1600.00115.3515.40-11,803-0.06%
2024/02/0200.00815.0014.90-81,811-0.44%
2024/02/0100.00114.9515.05-11,822-0.05%
太景抗流感病毒新藥 正式向中國藥監局申請上市許可UDN聯合新聞網－2024/08/04
太景*-KY（4157）4日晚間公告，接獲合作夥伴健康元藥業集團通知，太景開發的抗流感病毒新藥Pixavir (TG-1......詳全文
太景*-KY流感抗病毒新藥三期臨床 提前完成收案750人Anue鉅亨－2024/01/08
...詳全文
太景新藥 取得俄國藥證UDN聯合新聞網－2022/08/29
太景*-KY （4157）昨（28）日代子公司太景生技公告，抗生素新藥奈諾沙星靜脈輸液（500 mg/250 ml）已獲......詳全文
太景*-KY 相關文章